The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study

Table 1

The summary of patient characteristics.

Charateristics		N
	Age	53 (median, range: 39–68)
	Gender
	Female	3 (33.3%)
	Male	6 (66.7%)
	ECOG
	0	5 (55.6%)
	1	2 (22.2%)
	2	2 (22.2%)
	Child–Pugh
	A	7 (77.8%)
	B	2 (22.2%)
	C	0
	Max tumor size (cm)	70.7 ± 30.0 (average, range 33–130)
	Prior lines of treatment
	1	6 (66.7%)
	2	1 (11.1%)
	3	2 (22.2%)
	Previous treatment regimen
1st line	Gemox + levatinib + PD-1	7
	GP + PD-1	2
2st line	capecitabine + nanoparticle albumin-bound (NAB) paclitaxel	2
	FGFR2 inhibitor (clinical trial)	1
3st line	Gemox + Levatinib + PD-1 inhibitor	2
	CA19-9 at baseline
	Positive	5 (55.6%)
	Negtive	4 (44.4%)
	HAIC cycles	2.9 (average, range 1–5)

ECOG: the Eastern Cooperative Oncology Group performance status; Gemox: oxaliplatin plus gemcitabine regimen; GP: gemcitabine plus cisplatin regimen; CA19-9 positive: serum CA19-9 expression above 34 U/L; and PD-1 inhibitors: patients chose different PD-1 inhibitors including pembrolizumab, tislelizumab, and Sintilimab.